- Home
- ASGN vs GLPG Comparison
ASGN vs GLPG Comparison
Compare ASGN & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASGN
- GLPG
- Stock Information
- Founded
- ASGN 1985
- GLPG 1999
- Country
- ASGN United States
- GLPG Belgium
- Employees
- ASGN N/A
- GLPG N/A
- Industry
- ASGN Professional Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- ASGN Consumer Discretionary
- GLPG Health Care
- Exchange
- ASGN Nasdaq
- GLPG Nasdaq
- Market Cap
- ASGN 2.1B
- GLPG 2.1B
- IPO Year
- ASGN 1992
- GLPG 2005
- Fundamental
- Price
- ASGN $45.64
- GLPG $31.20
- Analyst Decision
- ASGN Hold
- GLPG Hold
- Analyst Count
- ASGN 5
- GLPG 4
- Target Price
- ASGN $46.60
- GLPG $31.33
- AVG Volume (30 Days)
- ASGN 642.1K
- GLPG 150.4K
- Earning Date
- ASGN 10-22-2025
- GLPG 11-05-2025
- Dividend Yield
- ASGN N/A
- GLPG N/A
- EPS Growth
- ASGN N/A
- GLPG N/A
- EPS
- ASGN 2.96
- GLPG N/A
- Revenue
- ASGN $3,985,300,000.00
- GLPG $336,643,201.00
- Revenue This Year
- ASGN N/A
- GLPG $1.77
- Revenue Next Year
- ASGN $0.62
- GLPG $0.44
- P/E Ratio
- ASGN $15.33
- GLPG N/A
- Revenue Growth
- ASGN N/A
- GLPG 10.31
- 52 Week Low
- ASGN $39.25
- GLPG $22.36
- 52 Week High
- ASGN $95.29
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- ASGN 54.69
- GLPG 46.80
- Support Level
- ASGN $39.25
- GLPG $30.13
- Resistance Level
- ASGN $46.49
- GLPG $31.27
- Average True Range (ATR)
- ASGN 1.62
- GLPG 0.69
- MACD
- ASGN 0.45
- GLPG 0.06
- Stochastic Oscillator
- ASGN 87.71
- GLPG 34.11
About ASGN ASGN Incorporated
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.